Browse News
Filter News
Found 9 articles
-
Synthekine Announces Presentation of Initial Results from Phase 1a/1b Clinical Trial of STK-012 at AACR 2024 Annual Meeting
3/7/2024
Synthekine Inc today announced that data from a Phase 1a/1b clinical trial of its α/β biased IL-2 partial agonist, STK-012, will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024 taking place in San Diego, from April 5-10, 2024.
-
First Patient Dosed in Phase 1b Clinical Trial of Synthekine’s α/β Biased IL-2, STK-012, for Treatment of Solid Tumors
9/28/2023
Synthekine Inc., a leader in engineered cytokine therapeutics, today announced that the company has completed phase 1a dose escalation and dosed the first patient in the Phase 1b portion of a clinical trial evaluating its α/β biased IL-2, STK-012, for the treatment of solid tumors.
-
Synthekine Secures $100 Million Series C Financing to Advance Pipeline of Engineered Cytokine Therapeutics
1/6/2023
Synthekine Inc. today announced the closing of a $100 million Series C financing led by The Column Group, with participation from both new and existing investors.
-
Fierce Biotech Names Synthekine as One of Its “Fierce 15” Biotech Companies of 2022
9/12/2022
Synthekine Inc. , an engineered cytokine therapeutics company, today announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.
-
Synthekine Doses First Patient in Phase 1 Clinical Trial of IL-2 Partial Agonist, STK-012, for Treatment of Solid Tumors
2/3/2022
Synthekine Inc. , an engineered cytokine therapeutics company, today announced the dosing of the first patient in a Phase 1a/1b clinical trial of its IL-2 partial agonist, STK-012.
-
Under the agreement, Merck can use Synthekine's surrogate cytokine agonist platform to discover, develop, and sell new cytokine-based treatments for up to two cytokine targets.
-
Clinical Catch-Up: October 25-29
11/1/2021
Yet another busy week for clinical trial news. Here’s a look. -
Synthekine Advances IL-2 Partial Agonist, STK-012, into Clinical Investigation for Treatment of Solid Tumors
10/28/2021
Synthekine Inc. today announced it is advancing its IL-2 partial agonist, STK-012, into clinical investigation following clearance of its investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA).
-
Asher Bio began two years ago and raised $55 million in a Series A financing round this March to take forward a series of engineered cytokines that aim to eliminate both the toxicities and the loss of efficacy in immunotherapy.